Biomedicine represents one of the main study areas for dendrimers, which have proven to be valuable both in diagnostics and therapy, due to their capacity for improving solubility, absorption, bioavailability and targeted distribution. Molecular cytotoxicity constitutes a limiting characteristic, especially for cationic and higher-generation dendrimers. Antineoplastic research of dendrimers has been widely developed, and several types of poly(amidoamine) and poly(propylene imine) dendrimer complexes with doxorubicin, paclitaxel, imatinib, sunitinib, cisplatin, melphalan and methotrexate have shown an improvement in comparison with the drug molecule alone. The anti-inflammatory therapy focused on dendrimer complexes of ibuprofen, indomethacin, piroxicam, ketoprofen and diflunisal. In the context of the development of antibiotic-resistant bacterial strains, dendrimer complexes of fluoroquinolones, macrolides, beta-lactamines and aminoglycosides have shown promising effects. Regarding antiviral therapy, studies have been performed to develop dendrimer conjugates with tenofovir, maraviroc, zidovudine, oseltamivir and acyclovir, among others. Furthermore, cardiovascular therapy has strongly addressed dendrimers. Employed in imaging diagnostics, dendrimers reduce the dosage required to obtain images, thus improving the efficiency of radioisotopes. Dendrimers are macromolecular structures with multiple advantages that can suffer modifications depending on the chemical nature of the drug that has to be transported. The results obtained so far encourage the pursuit of new studies.

Quality by Design (QbD) concept in drug formulation and development was introduced in order to achieve and ensure a proper product quality through a good process understanding. By identifying the variability sources that influence the product characteristics, the product quality can be built from the development phase. By applying this concept, in the present experimental work was intended to develop and evaluate orodispersible tablets (ODTs) with paracetamol. In order to reach a good balance between their properties: quick disintegration, convenient hardness and a fast drug release, a statistical method was used. 36 formulations were prepared according to a D-optimal experimental design. The formulation factors used in the design were: the type of the diluent agent, the type of disintegrate agent, and the percentages of the disintegrant, sweetener and flavour. The obtained tablets were analysed in vitro for their friability, disintegration time, wetting time and dissolution profile. During this experiment it was observed that the mechanical properties were mainly influenced by the type of diluent agent used, the disintegrant agent and it's ratio in each formulation. The percentage of sweetener and flavour also influenced the dissolution profile, beside the other formulation variables. QbD approach was successfully applied within this study and the ODTs with paracetamol that have desired pharmaceutical characteristics may be successfully prepared. RezumatConceptul de calitate prin design (QbD) a fost introdus în formularea şi dezvoltarea medicamentelor pentru a obţine şi a asigura o calitate adecvată produsului, având la bază o mai bună înţelegere a procesului. Calitatea produsului poate fi construită din faza de dezvoltare a acestuia, prin identificarea surselor de variabilitate care îi pot influenţa caracteristicile. Aplicând acest concept, în prezenta lucrare s-a urmărit obţinerea şi caracterizarea unor comprimate orodispersabile cu paracetamol, care să prezinte o dezagregare rapidă, o bună rezistenţă mecanică şi un profil de cedare in vitro optim. Pentru acest lucru s-au preparat 36 de tipuri de comprimate, conform unui plan experimental de optimizare. Variabilele de formulare au fost: tipul de diluant, tipul de dezagregant şi procentele de dezagregant, ȋndulcitor şi aromatizant. În vederea obţinerii unor variabile de răspuns, comprimatele au fost evaluate in vitro. Au fost evaluate friabilitatea, dezagregarea, rezistenţa mecanică, timpul de umectare şi profilul de dizolvare. Friabilitatea, dezagregarea şi rezistenţa mecanică au fost influenţate de tipul excipientului diluant folosit, de dezagregantul utilizat, dar şi de concentraţia acestuia. Profilul de dizolvare a fost influ enţat, pe lângă factorii amintiţi anterior şi de procentul de îndulcitor sintetic, dar şi de concentraţia aromatizantului. Conceptul de calitate prin design a fost aplicat cu succes acestui studiu, comprimatele orodispersabile obţinute având caracteristicile dorite.

The aim of this study was the development and formulating of an eye contour serum containing hyaluronic acid (HA) and the assessment of stability tests performed for the cosmetic product, transfered into a glass cosmetic bottle with polipropylene (PP) pump and cap. Sample of cosmetic serum were stored using 20 mL glass bottles with PP (Polypropylene) pump and cap. The developed cosmetic formulation was monitored under accelerated stability studies, performed over a period of 30 days while maintaining the product at 4, 20 and 40�C. Quality control initial, and after initiating the accelerated stability test was performed for the developed cosmetic formulation.

In Romania, antidiabetic medication is free, based on a program of the Ministry of Public Health: "Treatment of patients with diabetes mellitus". Since October 1, 2006, antidiabetic drugs have been delivered through open circuit pharmacies in contractual relationship with the National Health Insurance House, after four years of centralized delivery through hospital pharmacies. Objectives: This study aims to describe the influences of the diabetes treatment regarding patients' quality of life and their satisfaction. Methods: A cross-sectional descriptive study was performed in pharmacies. The study includes 477 patients with diabetes mellitus from Cluj County, Romania. The interviewing method was used on a questionnaire base. The participants included in the study admitted to participate in May-June, 2016. The questionnaire was systematically developed following comprehensive literature review and structured according to 3 main fields: 1) patient demographics; 2) diabetes patient treatment and 3) glycaemia control and patient satisfaction. Results: The research performed in two months showed that 78% of the respondents used oral antidiabetics for treatment, more than 19% of the inquired patients reached normal glycaemia values following antidiabetic treatment, and about 82% of patients were satisfied with the current system of acquisition of antidiabetic drugs. Conclusions: The treatment with antidiabetic drugs maintains a relatively good health status. Also, the life expectancy of diabetic patients has increased over the past period.

Introduction: Infertility represents a problem for more and more couples all over the world, including in Romania. Thus, more and more women need to resort to drugs to treat infertility, treatments which are not without adverse reactions (Boivin et al., 2007). Modern therapy brings significant benefits in the treatment of infertility. Despite all the benefits, the controlled ovarian stimulation treatment does not lack the possibility of adverse reactions to the administered drugs. Objectives: The aim of this study was to determine the potential adverse reactions experienced by patients during the treatment with gonadotropins followed by assisted conception Methods: A study was done based on a questionnaire which included the adverse reactions comprised in the SmPCs (Summaries of Product Characteristics) of the original drugs, and also based on the adverse reactions frequently reported in clinical studies. The questionnaire was distributed in the online environment, from May 2018 to July 2018, in Romania, to patients to whom at least one of the analysed gonadotropins (corifollitropin alpha, follitropin alpha, follitropin beta, follitropin alpha/follitropin beta, menotropin, urofollitropin) was administered during the controlled ovarian stimulation treatment, in the routine practice of assisted human reproduction technology. Results: The results show that a total number of 319 events suspected of being adverse reactions was reported, grouped on the highest MedDRA level, SOC (system – organ- class), with an average of 8.18 adverse reactions (AR)/patient. Conclusions: The results of the study demonstrate the fact the disorders appeared after drug administration in the controlled ovarian stimulation treatment in the context of the routine practice of assisted human reproduction technology, were considered adverse reactions by the patients.